000170571 001__ 170571
000170571 005__ 20240229133717.0
000170571 0247_ $$2doi$$a10.3390/cancers13174385
000170571 0247_ $$2pmid$$apmid:34503195
000170571 0247_ $$2altmetric$$aaltmetric:113276416
000170571 037__ $$aDKFZ-2021-02022
000170571 041__ $$aEnglish
000170571 082__ $$a610
000170571 1001_ $$aHemminki, Kari$$b0
000170571 245__ $$aFamilial Risks and Proportions Describing Population Landscape of Familial Cancer.
000170571 260__ $$aBasel$$bMDPI$$c2021
000170571 3367_ $$2DRIVER$$aarticle
000170571 3367_ $$2DataCite$$aOutput Types/Journal article
000170571 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1631695970_23619
000170571 3367_ $$2BibTeX$$aARTICLE
000170571 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000170571 3367_ $$00$$2EndNote$$aJournal Article
000170571 520__ $$aFamilial cancer can be defined through the occurrence of the same cancer in two or more family members. We describe a nationwide landscape of familial cancer, including its frequency and the risk that it conveys, by using the largest family database in the world with complete family structures and medically confirmed cancers.We employed standardized incidence ratios (SIRs) to estimate familial risks for concordant cancer among first-degree relatives using the Swedish Cancer Registry from years 1958 through 2016.Cancer risks in a 20-84 year old population conferred by affected parents or siblings were about two-fold compared to the risk for individuals with unaffected relatives. For small intestinal, testicular, thyroid and bone cancers and Hodgkin disease, risks were higher, five-to-eight-fold. Novel familial associations included adult bone, lip, pharyngeal, and connective tissue cancers. Familial cancers were found in 13.2% of families with cancer; for prostate cancer, the proportion was 26.4%. High-risk families accounted for 6.6% of all cancer families.High-risk family history should be exceedingly considered for management, including targeted genetic testing. For the major proportion of familial clustering, where genetic testing may not be feasible, medical and behavioral intervention should be indicated for the patient and their family members, including screening recommendations and avoidance of carcinogenic exposure.
000170571 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000170571 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000170571 650_7 $$2Other$$afamilial proportion
000170571 650_7 $$2Other$$afamilial risk
000170571 650_7 $$2Other$$afamily-cancer database
000170571 650_7 $$2Other$$ahigh-risk families
000170571 650_7 $$2Other$$anationwide study
000170571 7001_ $$aSundquist, Kristina$$b1
000170571 7001_ $$00000-0001-7228-5015$$aSundquist, Jan$$b2
000170571 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b3$$udkfz
000170571 7001_ $$00000-0001-7103-8530$$aHemminki, Akseli$$b4
000170571 7001_ $$aLi, Xinjun$$b5
000170571 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers13174385$$gVol. 13, no. 17, p. 4385 -$$n17$$p4385$$tCancers$$v13$$x2072-6694$$y2021
000170571 909CO $$ooai:inrepo02.dkfz.de:170571$$pVDB
000170571 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000170571 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000170571 9141_ $$y2021
000170571 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2019$$d2021-05-04
000170571 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-05-04
000170571 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-05-04
000170571 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-05-04
000170571 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-04
000170571 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-04
000170571 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-05-04
000170571 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000170571 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-05-04
000170571 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-05-04
000170571 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-05-04
000170571 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000170571 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-05-04
000170571 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-05-04
000170571 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000170571 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-05-04
000170571 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2019$$d2021-05-04
000170571 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000170571 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000170571 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000170571 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000170571 980__ $$ajournal
000170571 980__ $$aVDB
000170571 980__ $$aI:(DE-He78)B062-20160331
000170571 980__ $$aI:(DE-He78)HD01-20160331
000170571 980__ $$aUNRESTRICTED